PDSB stock forecast, quote, news & analysis
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States... Show more
Why PDS Biotechnology (PDSB) Stock Is Down -34% in the Last 30 Days
Key Takeaways
- PDSB has declined roughly 34% over the last 30 days, from about $1.52 on October 12 to near $1.00, after a sharp multi-week run higher.
- The pullback follows a speculative rally sparked by a private investment in public equity (PIPE) financing led by Dr. Patrick Soon-Shiong's Nant Capital, announced in early September.
- Despite the recent drop, shares remain up roughly 290% over the trailing quarter, having recovered dramatically from levels below $0.30 in mid-August.
- Heavy equity issuance in the PIPE — approximately 20.9 million shares plus about 20.4 million warrants priced at $0.2825 per unit — has raised dilution concerns that are pressuring sentiment.
- With no approved products or revenue, PDSB is a clinical-stage biotech whose stock remains highly sensitive to clinical, regulatory, and financing headlines.
- For additional context on valuation and catalysts, explore PDSB's Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are approaching this ticker, visit Tickeron's Trending AI Robots.
PDS Biotechnology (PDSB) Company Overview and Market Position
PDS Biotechnology Corporation is a clinical-stage immunotherapy company headquartered in Princeton, New Jersey, developing targeted cancer immunotherapies. Its lead program, PDS0301 (also referred to as PDS01ADC or NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure. The company also owns the Versamune cancer vaccine platform, including PDS0101, an investigational immunotherapy targeting HPV16-positive cancers.
The company has no approved products and generates no product revenue, and it reported a net loss of approximately $7.3 million for the first quarter of 2026, with cash of about $21.7 million as of March 31, 2026. Investors follow PDSB primarily for its clinical data readouts and financing developments, which have historically driven large swings in the share price.
PDS Biotechnology (PDSB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PDSB has moved from a closing price of approximately $1.52 on October 12 to roughly $1.00, a decline of about 34%. The stock peaked intraday near $1.60 in mid-October before giving back much of that advance through late October and early November.
The broader quarterly picture tells a different story. Following a strategic reset in mid-August that sent shares to roughly $0.26, the stock surged on a combination of new financing and clinical data, climbing roughly 290% to current levels near $1.00. This means the recent 34% pullback has retraced only a portion of a much larger quarterly gain, underscoring the stock's extreme volatility.
What Drove PDSB Stock Price in the Last 30 Days
The last 30 days have been defined by a sharp reversal from the stock's parabolic September–October advance. After the September PIPE announcement, PDSB rallied from around $0.22 in early September to more than $1.00 within weeks, a move amplified by the stock's small float and heavy retail-driven trading volume. As that momentum faded, profit-taking and position unwinding pushed shares lower.
Dilution has also weighed on sentiment. The financing announced September 8, 2026, led by Nant Capital with participation from existing investors, was structured to raise up to $22.55 million, with an initial closing expected to generate roughly $11.55 million. The transaction issued approximately 20.9 million shares (or pre-funded warrants in lieu of shares) alongside about 20.4 million common warrants, with units priced at $0.2825 — a level well below the stock's October peak. This substantial increase in share count and low-priced warrant overhang has been a key source of downward pressure as the rally cooled.
Additionally, PDSB has been trading near the Nasdaq Capital Market's $1.00 minimum bid price requirement, adding technical and listing-related uncertainty around the share price. With no near-term revenue and a milestone-dependent capital structure, the stock remains prone to sharp swings on limited news flow.
What Drove PDSB Stock Performance Over the Last Quarter
The dominant event of the quarter was the company's strategic refocus. In mid-August, PDS Biotech announced a realignment around its lead asset PDS0301, accompanied by a workforce reduction and leadership changes. The shares fell sharply to about $0.26 as investors absorbed the strategic shift away from the VERSATILE-003 Phase 3 program for PDS0101.
The recovery began in early September, when the company unveiled the PIPE financing led by Dr. Patrick Soon-Shiong, founder of NantWorks. The capital was earmarked to advance PDS0301 into late-stage clinical development, supported by interim Phase 2 data in metastatic colorectal cancer showing encouraging response and survival outcomes. Positive published clinical data — including VERSATILE-002 Phase 2 results in HPV16-positive head and neck cancer and PDS01ADC results across colorectal and prostate cancer — reinforced the turnaround narrative and drove the stock's multi-fold quarterly rebound.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that actively monitor thousands of tickers, but only the top-performing and most relevant strategies appear in the curated Trending AI Robots section. These bots vary widely in strategy, timeframe, and performance metrics, giving traders a filtered view of the approaches currently generating the strongest signals across the market. For those following volatile, catalyst-driven names like PDSB, the section provides a useful way to see how automated systems are positioning across momentum, trend, and swing strategies. Explore the Trending AI Robots page to review current top performers and consider whether algorithmic insights fit your research process.
PDSB Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for PDSB include the timing and content of upcoming financial results and management's update on cash runway, given the modest cash balance reported earlier in 2026. Investors should also monitor the milestone closing of the PIPE, which is tied to the submission of a registrational Phase 3 clinical trial protocol for PDS0301 to the FDA, as well as additional colorectal cancer data the company has indicated it expects by year-end.
Clinical and regulatory progress on PDS0301, the restart of enrollment in the amended VERSATILE-003 trial, and any updates on the PDS0101 licensing option granted to NantWorks will be closely watched. Competition from other late-stage programs in the HPV16 head and neck space, including BioNTech, and the ongoing need to maintain Nasdaq listing compliance above $1.00 remain key risks. As always, PDSB's outlook depends heavily on clinical data, financing, and regulatory milestones rather than near-term financial performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PDSB's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 73 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology